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Abstract 
Tumor remains a challenging task for oncology community. Drug resistance due to chemotherapy 
remain principal impediments toward potential therapeutic strategies. Development of novel anti-cancer 
drugs or new targeted strategies to conquer drug resistance is a key goal of cancer research. In this 
respect, novel tumor gatekeepers and innovative targeted strategies can be helpful in overcoming drug 
resistance as well as improve currently used targeted therapies. In this review, efforts have been made 
to present some of the latest knowledge about novel tumor gatekeepers and new therapeutic strategies 
to improve the efficacy of chemotherapy and give new hope to cancer patients to fight against cancer. 
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Cancer is one of the main causes of human 
deaths worldwide. . Cancer is defined as a 
cluster of disorders characterized by 
unrestrained growth and multiplication of 
abnormal cells. Uncontrolled multiplication of 
abnormal cells leads to death. Approximately, 
cancer accounts one in four deaths. Life time 
cancer threat in women is (38 %) and men (42 
%) in the United States. American Cancer 
Society has reported that about 1,685,210 new 
cancer cases and nearly 595,690 deaths will be 
occurred in 2016 [1]. In 2017, approximately 
600,920 peoples will be died from cancer [2]. 
 
Advances in cancer biology have led to 
development of novel anti-cancer drugs [3]. 
Efficacy of novel anti-cancer drugs is limited due 
to development of resistance as well as 
substantial toxicity. Recent studies have reported 
that resistance to chemotherapy is a main 
obstacle for efficient targeted cancer therapies 
[4,5]. To control cancers, there is urgent need to 
identify novel tumor gatekeepers and 
establishment of promising therapeutic 
approaches.  In this review, we shed light on the 
recently identified new tumor gatekeepers and 
promising therapeutic approaches to conquer 
drug resistance. 
 
Role of novel tumor gatekeepers in cancer 
suppression 
 
Activation of the AKT oncogenic pathway through 
mutations in PIK3CA or PTEN loss is frequently 
occurred in many types of cancers; however, 
targeting of AKT pathway is a challenging task 
Zahid et al 
Trop J Pharm Res, October 2017; 16(10): 2546  
 
due to mechanism-based toxicities of the 
inhibitors which target inactive conformation of 
the AKT. A novel potent ATP-competitive 
inhibitor of the AKT (Ipatasertib), effectively 
targets active phosphorylated AKT [6].  
 
More recent study has reported that this novel 
inhibitor confers vigorous and safe targeting of 
AKT in solid tumors. Authors have found that this 
inhibitor is tolerated; majority of the adverse 
events are gastrointestinal and grade 1-2 in 
severity. Exposure of novel inhibitor ≥200 mg 
everyday in cancer patients is associated with 
TGI90, and results show that this selective novel 
inhibitor actively inhibits multiple targets such as 
mTOR, GSK3β and PRAS40 in paired on-
treatment biopsies.  Inhibition of the AKT 
signaling by with ipatasertib is correlated with 
significant control of cancer and tolerable safety 
profile in cancer patients. Targeting of 
phosphorylated AKT by using ATP-competitive 
inhibitor grants superior therapeutic window 
compared to allosteric inhibitors. Novel 
Ipatasertib inhibitor could be tumor gatekeeper in 
AKT-mediated human cancers [6]. 
 
Hepatocellular carcinoma is a severe human 
cancer. Fibroblast growth factor 19 is a ligand for 
the fibroblast growth factor 4 (FGF4) and plays 
critical role in hepatocellular carcinoma. 
Recently, it has been reported that novel potent 
inhibitor ASP5878 which successfully inhibits 
FGFR1, 2, 3 and 4, and also suppresses growth 
of FGF19-expressing hepatocellular carcinoma. 
This novel inhibitor suppresses the kinase 
activity of FGF4 with an IC50 of 3.5 nmol/L. 
Moreover, this potent inhibitor suppresses FGF4 
phosphorylation as well as its downstream 
signaling molecules and plus induces apoptosis. 
Furthermore, oral administration of ASP5878 (3 
mg/kg) induces maintained tumor regression in 
the subcutaneous xenograft mouse model using 
Hep3B2.1-7, whereas ASP5878 induces 
complete tumor regression in HuH-7, an 
orthotopic xenograft mouse model. These 
outcomes demonstrate that ASP5878 is a 
gatekeeper of hepatocellular carcinoma with 
tumors expressing FGF19 [7]. 
 
Polycomb repressive complex 2 (PRC2) 
regulates epigenetic states essential for 
homeostasis and development. This complex 
causes H3K4 trimethylation, consequently 
leading gene silencing and is deregulated in 
human cancers [8]. PRC2 is comprised of 3 core 
subunits, SUZ12, EED and EZH2, and controls 
transcriptional regulation. EZH2 is associated 
with the histone H3K3 methylation, and activity of 
EZH2 is increased after EED binding to the 
trimethylated H3K27.  
More recent study has identified a selective and 
potent inhibitor EED226 which inhibits PRC2 by 
directly binding to EED H3K27me3 binding 
pocket [9]. This potent inhibitor induces a 
conformational change following binding of EED, 
and leads to loss PRC2 activity. Activity of this 
novel inhibitor is similar to SAM-competitive 
inhibitors in suppressing H3K27 methylation of 
the PRC2 target genes and inducing regression 
of the lymphoma xenograft tumors. Captivatingly, 
potent EED226 efficiently inhibits PRC2 
containing a mutant EZH2 protein which cannot 
be inhibited by using SAM-competitive inhibitors. 
These novel findings show that a novel inhibitor 
EED226 successfully inhibits the activity of PRC2 
through an allosteric mechanism and could be an 
authoritative gatekeeper of PRC2-dependent 
human cancers [9]. 
 
Moreover, another novel potent inhibitor A-395 
has been reported which inhibits PRC2 complex 
activity via inhibiting EED protein-protein 
interaction. The results reveal that this novel 
inhibitor binds to the EED in the binding pocket of 
H3K27 trimethylation, thereby stopping allosteric 
activation of PRC2 catalytic activity. Activity of 
this potent inhibitor is similar to PRC2 enzymatic 
inhibitors both in vivo and in vitro; however, this 
potent inhibitor maintains its potent activity in 
response to those cell lines which show 
resistance against catalytic inhibitors. Thus, 
potent inhibitor A-395 represents a first-in-class 
antagonist of the PRC2 protein-protein 
interactions for use as a chemical probe for the 
investigation of novel functions of EED-
containing protein complexes [8]. 
 
Protein lysine methyltransferases (PKMTs) are 
regulators of various physiological processes 
including transcription and genomic integrity 
maintenance. Genetic evidence shows that 
PKMTs (SUV420H1 and SUV420H2) promote 
non-homologous end-joining (NHEJ)-directed 
DNA repair  via catalyzing  di-and tri-methylation 
of lysine 20 on histone 4 [10]. Recently, 
Scientists have identified a selective and potent 
inhibitor A-196 which inhibits both the SUV420H1 
and SUV420H2. Results show that A-196 is 
substrate-competitive inhibitor of SUV420H1 and 
SUV420H2 enzymes. This potent inhibitor 
induces a global reduction of H4K20me2 as well 
as H4K20me3 and plus a concomitant 
amplification of H4K20me1 in cells. This inhibitor 
inhibits foci formation of 53BP1 following ionizing 
radiation and decreases NHEJ-mediated DNA 
defects repair but does not affects homology-
directed DNA repair. These novel outcomes 
show the significance of enzymatic activity of 
SUV4-20 in DNA repair H4K20 methylation. This 
potent inhibitor represents also a first-in-class 
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SUV4-20 chemical probe in the investigation of 
importance of histonemethyltransferase in the 
genomic integrity [10].  
 
Colden et al (2017) have reported that miRNA-
466 suppresses tumor growth and bone 
metastasis in the prostate tumor through direct 
regulation of RUNX2 osteogenic transcriptional 
factor. Results show that miR-466 is under-
expressed in prostate tumor as compared to 
normal tissues. miR-466 reconstitution in 
metastatic prostate cancer cell lines impairs their 
oncogenic role including cell proliferation and 
invasion, and also induces apoptosis and cell 
cycle arrest as compared to control miRNA. On 
the contrary, miR-466 attenuation induces 
tumorigenic features in normal prostate cells. 
Moreover, miR-466 inhibits growth of prostate 
cancer and metastasis by targeting RUNX2 
transcriptional factor. mir-466 overexpression 
leads to downregulation of integrated network of 
RUNX2 target genes such as osteocalcin, 
osteopontin, MMP11, ANGPTs including FAK, 
pAkt, Fyn and vimentin that are associated with 
invasion, migration, angiogenesis, metastasis 
and EMT. Furthermore, miR-466 suppresses 
growth of primary orthotopic tumor and 
spontaneous metastasis to bone.  
 
Kaplan-Meir and receiver operating curve 
analyses indicate that expression of miR-466 is 
discriminated between malignant and normal 
prostate tissues; and predicts biochemical 
relapse. These findings establish that miR-466-
mediated attenuation of transcriptional factor 
RUNX2 as a new therapeutic tool for regulating 
growth of prostate cancer, especially metastasis 
to bone. For the first time, anti-bone function and 
clinical importance of miR-466 has been 
documented in the prostate cancer [11]. 
 
Cancer stem cells (CSCs) contribute to tumor 
recurrences and chemoresistance [12]. Recently, 
it has been reported that enforced miR-141 
expression in CD44t and bulk PCa cells 
suppresses properties of CSCs such as invasion, 
sphere formation and holoclone, and inhibits 
tumor regeneration and metastasis. The 
expression of miR-141 enforces a powerful 
epithelial phenotype with an incomplete 
mesenchymal phenotype loss. Whole-genome 
RNA sequencing has uncovered new miR-141-
regulated molecular targets in in prostate cancer 
(PCa) cells including Rho GTPas family 
members such as ARPC5, CDC42, RAC1 and 
CDC42EP3 and stem cell molecules EZH2 and 
CD44, these are direct targets of miR-141. These 
novel findings demonstrate that miR-141 
hampers tumor growth and metastasis via 
employing multiple mechanisms [13]. 
Latest study has presented a new presented a 
new chemoresistant prostate cancer patient-
derived xenograft (PDX) model in the NOD/SCID 
mice and discovered CD54 as a key gene among 
the highest enriched gene expression profiles in 
the prostate cancer exposed to chronic cisplatin 
admistration. Moreover, it has been observed 
that CD54 plays key role in tumorigenesis as well 
as self-renewal of prostate cancer stem cells. 
Knockdown of CD54 significantly decreases 
prostate cancer tumorigenesis both in vivo and in 
vitro and greatly extends survival time of tumor-
bearing mice in the prostate cancer xenograft 
model. Furthermore, it has been identified that 
p38-Notch1 axis is a major downstream signaling 
pathway in the CD54-mediated regulation of 
cancer stem cells in prostate tumors. These 
outcomes suggest that CD54 can be used as a 
prostate cancer stem cell marker and will provide 
a novel potential therapeutic target through 
CD54-Notch1 signaling in prostate cancer [12].  
 
Lung cancer is a most common cancer and 
leading cause of deaths worldwide. Targeted 
therapies with tyrosine kinase inhibitors (TKIs) 
have been designed for the epidermal growth 
factor receptor (EGFR) positive patients in the 
adenocarcinoma or mixed adenosquamus lung 
cancer patients. However, novel 
chemotherapeutic agents have been developed 
for EGFR, at same time new mutations have also 
been found following TKI administration. 
Currently, new mutation T790 has been identified 
and is highly prevalent in the patients already 
treated with a tyrosine kinase inhibitor [14]. 
Osimertinib is a third generation, oral, pyrimidine-
based, irreversible EGFR TKI which have got 
endorsement from FDA in 2015 to treat cancer 
patients with metastatic, EGFR T790M mutation-
positive NSCLC resistant to EGFR TKI therapy. 
Osimertinib has been also approved for cancer 
patients with EGFR T790M mutation-positive 
NSCLC resistant to EGFR TKI therapy in 
European Union, Japan and United Kingdom. 
These findings show that Osimertinib acts as a 
novel gatekeeper for cancer patients with EGFR 
T790M mutation-positive NSCLC [15]. 
 
Molecular mechanism underlying cross-talk 
tumor-associated macrophages and tumor cells 
which induce metastasis in lung cancer is poorly 
studied.  The scavenger receptor A1 (SR-A1) is 
primarily expressed in macrophages and is 
linked with lung cancer. Scientists have utilized 
transcriptomics, population genetics and 
functional analyses to explore how SR-A1 is 
engaged in lung tumorigenesis and its prognosis. 
They have investigated the SR-A1 genetic 
variants for feasible involvement in the survival of 
advanced-stage NSCLC patients in Harvard 
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Lung Cancer Study cohort. Results show that 2 
SNPs (rs1484751, rs17484273) in SR-A1 are 
linked with poor survival in this cohort. Significant 
SR-A1 downregulation in the lung tumor tissues 
has been observed. The involvement of SR-A1 
with prognosis has been validated in animal 
models in the context of metastasis of lung 
cancer. Macrophages obtained from mice 
genetically deficient for the SR-A1 exhibited 
faster metastasis in lung cancer model [16] 
(Figure 1). 
 
On the other hand, enhanced tumor cell seeding, 
invasion, migration and accumulation of 
macrophage in lung cancer tissue has been 
observed in SR-A1 deficient mice. Moreover, 
deletion of SR-A1 upregulates serum A1 (SAA1) 
in the macrophages through MAPK/Ik-B/NF-kB 
signaling. SAA1 promotes macrophage migration 
and tumor cell invasion in vivo, but these effects 
are blocked by anti-SAA1 antibody 
administration. Collectively, these novel findings 
explain how SR-A1 inhibits metastasis of lung 
cancer via downregulating production of SAA1 in 
tumor associated macrophages [16]. 
 
New strategies for drugging undrugable drug 
resistance 
Efficacy of tyrosine kinase inhibitors is 
satisfactory in the gastrointestinal stromal tumors 
(GISTs), but patients have received transitory 
benefits due to development of resistance to 
these inhibitors. Immunotherapy, especially 
blockade of ligand programmed death ligand 1 
(PD-L1) or inhibitory receptor programmed death 
1 (PD-1) has demonstrated well effectiveness in 
many types of cancers. Functional effects of 
PDL1 or PD-1 blockade remain elusive [17]. 
 
Scientists have identified that PD-L1/PD-1 
blockade increases the activity of T-cell and 
imattinib anti-cancer efficacy in GISTs. Authors 
have found that T-cell immunoglobulin mucin-3, 
inhibitory receptors PD-1 and lymphocyte 
activation gene 3 are upregulated on the tumor-
infiltrating T cells as compared to T cells from the 
matched blood. Meanwhile, variability has been 
found in intratumoral PD-L1 expression. 
Treatment with inhibitor imatinib abrogates IFNy-
mediated PD-L1 upregulation through inhibition 
of STAT1 in GIST cell lines. In KitV558Δ/+ mice, 
imatinib mediates downregulation of IFN-related 
genes and decreases expression of PD-L1 on 
the tumor cells.  
 
Blockade of both PD-L1 and PD-1 did not show 
any efficacy alone in vivo but increase imatinib 
anti-tumor effects via enhancing the function of 
T-cell effector in the existence of IDO and KIT 
inhibition. PD-L1/PD-1 blockade is a well 
therapeutic approach to improve the efficacy of 
GISTs targeted therapy [17]. 
 
 
Figure 1: Schematic representation of tumor gatekeepers. Tumor gatekeepers effectively inhibits the various 
tumor drivers such as AKT, PRC2, SUV420H1/H2, RUNX2, FGFRs, CSCs, and TWEAK-Fn14-NF-kB dependent 
signaling 
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Latest study has reported combination of 
adoptive cell therapy with vemurafenib in cancer 
patients with metastatic melanoma [18]. It has 
been observed that treatment is highly tolerated 
and shows safety profile same like TIL or 
vermurafenib alone. Among 11 cancer patients, 7 
patients have showed goal of clinical response 
while 2 cancer patients have showed complete 
response for three years. Importantly, one 
response has been gone for about 4 years. 
Viability and proliferation of the peripheral blood 
T cells and infusion bag TILS are suppressed in 
vitro with vermurafenib treatment under 
maximum vermurafenib serum concentration. 
TCRB repertoire (clone types, numbers, clonality, 
and frequency) and frequency) are not changed 
between, before and after vermurafenib lesions. 
Recognition of the autologous tumor via T cells is 
same between TILS is same between TILS 
grown from before and after vermurafenib 
metastases. Collectively, these findings show 
that coadminstration of TILS and vermurafenib is 
a feasible and safe granted target clinical 
response in clinical trial [18].  
 
Growing evidence have shown that critical driver 
genomic events influence response to targeted 
agents in colorectal cancer, which have been 
designed under ‘one gene, one drug’ archetype 
of the precision medicine. However, recent 
information about cancer genome complexity, 
patterns of tumor evolution under pressure of 
anti-cancer drugs as well as pharmacodynamic 
effects of the target suppression support change 
from a one gene, one drug strategy to a ‘multi-
gene, multi-drug’ approach during building 
therapeutic decisions. In colorectal cancer, 
transcriptomic subtypes characterization, 
encircling tumor, immune components and 
stromal have exposed dependencies of 
convergent pathway which mandate a ‘multi-
molecular’ viewpoint for designing targeted 
therapy to prevent this disease [19]. 
 
Therapy decision affects genetic landscape of 
the relapsed diseases. Scientists have identified 
that about 21 % relapsed patients treated with AL 
have acquired CYP19A1 (encoding aromatase) 
amplification (CYP19A1 amp). Furthermore, 
relapsed patients have acquired various 
mutations targeting major breast cancer-linked 
genes such as CYP19A1 and ESR1. Particularly, 
emergence of CYP19A1 amp cells has been found 
in vitro in Al-resistant models. Amplification of 
CYP19A1 increases activity of aromatase as well 
as binding of estrogen-independent ERα to 
target genes, as result CYP19A1amp cells 
revealed reduced sensitivity to Al treatment. 
These results show that Al treatment itself 
chooses for acquired CYP19A1amp and enhances 
local autocrine estrogen signaling in the Al-
resistant metastatic patients [20].  
 
Inhibition of SETD8 has been proposed a novel 
therapeutic approach for activation of p53 in the 
high-risk neuroblastoma. Given significance to 
scarcity of the druggable mutation in the high-risk 
neuroblastoma (NB), authors have undertaken 
chemical screens and epigenetic siRNA to 
explore epigenetic regulators important for 
blocking differentiation in high-risk 
neuroblastoma. High-content Opera imaging 
revealed that loss of 53 gene expression reduces 
cell proliferation in NB and 16 also induces 
differentiation. From these, SETD8, H4K20me1 
methyltransferase has been identified as a 
drugagable NB target through secondary 
chemical screen.  
 
Functional studies demonstrated that ablation of 
SETD8 rescued pro-apoptotic and cell cycle 
arrest p53 functions via reducing p53K382me1, 
promoting p53 canonical pathway activation. In 
the pre-clinical xenograft neuroblastoma models, 
pharmacological and genetic inhibition of SETD8 
confers a remarkable survival benefit, providing 
convincing evidence that targeting of SETD8 is a 
novel therapeutic approach in neuroblastoma 
[21]. 
 
Stunning successes of the immunotherapy have 
revolutionized oncology field, and emerged as 
promising approach for solid tumors. 
Immunotherapies possess different action 
mechanisms and include CSF-1R antibodies, 
monoclonal antibodies, check point inhibitors, 
such as PD1/PD-L1 or CTLA-4, and oncolytic 
viruses [22]. Moreover, recent evidences show 
that immunotherapy combined with radiation 
therapy is more effective than monotherapy 
alone. Preclinical studies reveal that expression 
of PD-L1 is increased in tumor cells following 
radiation therapy, resulting synergistically 
increased antitumor effect of PD-L1 blockade 
and irradiation. In clinical setting, those cancer 
patients which received radiation therapy before 
anti-PD-1 treatment showed remarkably better 
prognosis than those who didn’t receive radiation 
therapy [23].  
 
A recent study has shown that destabilized tumor 
vasculature causes poor drug delivery, harmful 
tumor environment, hypoxia and even metastasis 
[24]. Scientists have done a side-by-side ABTAA 
(Ang2-binding and Tie2-activating antibody) 
comparison and ABA (Ang2-blocking antibody) in 
mice with orthotopically implanted glioma, with 
unprompted mammary cancer and 
Zahid et al 
Trop J Pharm Res, October 2017; 16(10): 2550  
 
subcutaneously implanted Lewis lung carcinoma. 
They have found that Tie2 activation induces 
tumor vascular normalization, promoting 
increased blood perfusion and delivery of 
chemotherapeutic drugs, noticeably reduces 
lactate acidosis, and decreases growth of tumor 
and metastasis. Furthermore, ABTAA positively 
alters profile of immune cell within tumors. These 
results demonstrate that simultaneous inhibition 
of Ang2 and activation of Tie2 shape a power full 
therapeutic window to build a sound tumor 
environment and successful chemotherapeutic 
agents delivery into tumors [24]. 
 
Genomic landscapes of cancers have been 
explored through The Cancer Genome Atlas. 
Similarly, immunotherapy has also transformed 
human cancer treatments. Unfortunately, a wide 
range of cancer patients do not respond to 
immunotherapy, suggesting the urgent need to 
identify predictive markers and resistance 
mechanism an area of powerful cancer study 
[25]. Recent evidence shows that 
immunosuppressive action of the regulatory T 
cells is a major mechanism which limits success 
of immunotherapies with checkpoint blockers 
[26]. It has been reported that genotype-
immunophenotype associations and predictors of 
response to the checkpoint blockade can be 
identified through pan-cancer immunogenic 
analyses. To better understand tumor-immune 
cell interation, recent studies has characterized 
cancer antigenomes and intratumoral immune 
landscapes from twenty solid tumors and 
generated The Cancer Immune Atlas [25]. 
 
The hypothesis of cancer immunoediting 
suggests a dual function of immune system: 
protecting host through eliminating cancer cells, 
and shaping developing cancer via editing 
cancer genomes. Therefore, to what extent 
immunoediting shapes cancer genome in human 
malignancies is matter of debate. Furthermore, 
impact of immunotherapy with checkpoint 
blockers on modulating immunoediting has been 
poorly studied. [27]. 
 
Results show that Tregs infiltration and 
checkpoint molecules activation are main tumor 
escape mechanisms. Markedly, impact of the 
neutral evolution on sculpting tumor outweighed 
immunoediting via T cell independent as well as 
T cell dependent mechanisms in progressing 
tumors. Scientists have also illustrated that PD-
1/PD-L1 pathway targeting potentiates 
immunoediting and makes tumor more 
homogenous. Also, these novel outcomes show 
that neutral evolution is a main force which 
sculpts tumor during progression, and blockade 
of checkpoint efficiently enforces T cell 
dependent immunoselective pressure in this 
model. These novel findings have significant 
implication for the basic research studies on 
resistance mechanisms to checkpoint blockade 
and for the clinical translation [27]. 
 
Recent study has reported that EIF4E activation 
via aurora kinase A illustrates a new druggable 
axis in the everolimus resistant cancer cells. It 
has been found that enhanced protein levels of 
AURKA promotes EIF4E phosphorylation and c-
MYC upregulation. Overexpression of 
endogenous AURKA has been detected in 
everolimus-resistant UGC cell models. AURKA 
mediated EIF4E phosphorylation, cap-dependent 
translation, and enhanced c-MYC protein levels. 
Targeting of AURKA through genetic knockdown 
or selective inhibitor, alisertib, reverses these 
events, leading to a decrease cancer cell survival 
in intrinsic and acquired resistant cell models. 
 
Molecular studies indicate that AURKA binds to 
and inactivates EIF4E negative regulator protein 
phosphates 2A (PP2A), leading to EIF4E 
activation and resistance to everolimus in an 
AKT-ERK1/2, and mTOR-independent manner. 
Results from tumor xenograft mouse models 
showed that everolimus-resistant cancer cells 
are sensitive to alisertib.   These data show that 
AURKA is strongly involved in EIF4E activation 
and cap-dependent translation. Targeting of 
AURKA-EIF4E-c-MYC axis through alisertib is a 
new therapeutic approach that could be 
applicable for those cancer subgroups that show 
upregulation of AURKA and c-MYC and EIF4E 
activation or everolimus-resistant tumors [28]. 
 
Latest study has reported that cancer stem cell 
marker CD271 is strongly involved in DNA 
damage response and drug resistance of 
melanoma cells. Results show that CD271 
expression controls those genes which are linked 
with drug response and DNA repair. It was found 
that 110 CD271-responsive genes are 
significantly expressed in melanoma metastasis, 
of which, RAD51AP1, TOP2A and NEK2 were 
potential drivers of melanoma metastasis. They 
have identified that CD71 is regulated by p53 
and in turn is required for an accurate p53-
dependent response to DNA-damaging drugs. 
This study has provided insight in a CD271-
mediated signaling network connecting CD271 
with drug response, DNA repair and metastasis. 
Targeting of CD271 will be potential therapeutic 
strategy for overcoming drug resistance [29]. 
 
Neuroendocrine prostate cancer (NEPC) is a 
severe malignancy, molecular mechanisms 
which control the occurrence of NEPC, 
particularly those which are the consequences of  
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Figure 2: Schematic representation of potential therapeutic approaches. These novel approaches 
effectively targets various oncogenic agents and provide new therapeutic window to treat human 
cancer 
 
treatment-induced inhibition of androgen receptor 
(AR), remain elusive. More recently, latest study 
has discovered that control of neural BRN2 
transcriptional factor (encoded by POU3F2) is a 
main driver of neuroendocrine prostate cancer 
and destructive tumor growth both in vivo and in 
vitro by using novel model of AR pathway 
inhibitor-resistant prostate cancer. Novel findings 
show that AR effectively suppresses the 
transcription of BRN2 which is needed for NEPC 
as well as BRN2-dependent regulation of NEPC 
marker SOX2. Underscoring its inverse 
correlation with the typical AR activity in the 
clinical samples, high expression of BRN2 was 
found in NETP cancers and was markedly 
enhanced in prostate cancer as compared to 
adenocarcinoma, particularly in the patients with 
low serum PSA. These findings have revealed a 
unique mechanism of AR-dependent control of 
NEPC, suggesting that BRN2 targeting is a novel 
approach to control neuroendocrin differentiation 
in the prostate cancer [30]. 
 
Squamous cell carcinoma in head and neck 
(HNSCC) is a common cancer but poorly 
explored, with adverse clinical results because of 
resistance to medication, recurrence and 
metastasis. Cancer stem cells have been found 
in the HNSCC, and expression of BMI1 is linked 
to these phenotypes, but therapeutic strategies 
to conquer chemotherapeutic resistance and 
overcome metastases have not been discovered 
yet. Latest study has reported that lineage 
tracing and genetic ablation which BMI1+ CSCs 
induce cervical lymph node metastasis and 
invasive growth in HNSCC mouse model. 
Primary HNSCC samples and this model hold 
extreme tumorigenic, invasive, and Cisplatin-
resistant BMI1+CSCs, which possess enhanced 
AP-1 activity which mediates invasive growth and 
metastasis of the HNSCC. Inhibition of the AP-1 
or BMI1 leads to sensitization of tumors to 
cisplatin-based chemical treatment, and it 
eradicate lymph node metastases via targeting 
bulk tumor and CSCs, indicating promising 
regimens to defeat resistance to medication and 




To win a battle against cancer, there is urgent 
need to identify novel tumor gatekeepers and 
establish new targeted therapeutic strategies. In 
this study, recent tumor gatekeepers and new 
therapeutic approaches have both been 
highlighted. It is hoped that this review will 
contribute to the efforts to overcome undruggable 
drug resistance and advance the design of new 
therapeutic windows for human treatment.  
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